Danaher to buy Beckman Coulter for $6.8M
Danaher has signed a definitive merger agreement to acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash (without interest). The transaction is valued at approximately $6.8 billion, including debt assumed and net of cash acquired.
Beckman, based in Orange County, Calif., develops and markets products that automate biomedical testing, while Danaher designs and markets products and services to medical, industrial and commercial customers.
Approval of the transaction by Danaher shareholders is not required. The transaction is expected to be completed in the first half of 2011. Beckman would become part of Danaher's Life Sciences & Diagnostics segment, joining Danaher's Leica, AB Sciex, Radiometer and Molecular Devices businesses.
Goldman Sachs is acting as financial advisor to Beckman in connection with the transaction. Latham & Watkins is serving as legal counsel to Beckman Coulter in connection with the transaction.
Beckman, based in Orange County, Calif., develops and markets products that automate biomedical testing, while Danaher designs and markets products and services to medical, industrial and commercial customers.
Approval of the transaction by Danaher shareholders is not required. The transaction is expected to be completed in the first half of 2011. Beckman would become part of Danaher's Life Sciences & Diagnostics segment, joining Danaher's Leica, AB Sciex, Radiometer and Molecular Devices businesses.
Goldman Sachs is acting as financial advisor to Beckman in connection with the transaction. Latham & Watkins is serving as legal counsel to Beckman Coulter in connection with the transaction.